Gender, AOga, AOfs, CAGexp at ATXN2, and presence/absence of amyotrophy, parkinsonism, dystonic manifestations and cognitive decline at baseline, were studied as potential modifier factor of disease progression according to both models (study duration model and disease duration model). Here, ATXN2 is linked to Parkinsonism.